This website is intended for healthcare professionals only

Newsletter      
Hospital Healthcare Europe
HOPE LOGO
Hospital Healthcare Europe

Share this article

Follow by Email
Facebook
Twitter

Sponsored: The benefits of working with the global leader in diagnostics to support the diagnosis of allergic and autoimmune diseases


30 October, 2019  



References

  1. Crameri R. Allergy 2013;68: 693-694.
  2. Park KHP, et al. Ann Lab Med 2018;38:23-31.
  3. Thermo Fisher Scientific. Data on File.
  4. Werkstetter KJ, et al. Gastroenterology 2017; doi: 10.1053/j.gastro.2017.06.002.
  5. Wulandari AA, Schulz J, Hartmann F, Dignass A, Stein J. Poster No 119 presented at 11th Congress of ECCO, Amsterdam, Netherlands, 2016 e 48.
  6. Matthson Alm L, et al. Clin Exp Rheumatol 2017;36(1):144-152.
  7. Alpini C, et al. (2010). “Role of a new FEIA assay in systemic connective tissue disease diagnosis.” EliA Journal(Special Edition 1): 3.
  8. Baptista-Fernandes I, et al. (2010). “Performance of a new screening test for connective tissue disease specific antibodies compared to HEp2 screening.” EliA Journal(Special Edition 1): 4.
  9. Bonroy C, et al. (2013). “Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation.” Clinical Chemistry and Laboratory Medicine 51(9): 1771-1779.
  10. Elhage, et al. (2013). “ANA SCREENING WITH THE ELIA CTD KIT IN PATIENTS WITH SYSTEMIC SCLEROSIS.” Controversies in Rheumatology & Autoimmunity (CORA).
  11. Jeong S, et al. PLoS ONE 2017;12(3).
  12. Korsholm T, et al. Scandinavian Journal of Rheumatology 2014;43:89.
  13. Martínez, MJ, et al. (2010). “A comparison between two enzyme-linked immunosorbent assays and an indirect immunofluorescence test for Antinuclear Antibodies screening.” EliA Journal(Special Edition 1): 5.
  14. Morozzi G, et al. (2012). “A new strategy to detect ANA: IIF HEp-2 cells at second level after the EliA CTD Screen test. Is the algorithm correct?” Immuno Diagnostics Journal 2: 3-4.
  15. Op De Beeck K, et al. Autoimmunity Reviews 2011;10(12): 801-808.
  16. Otten HG, et al Clin Exp Rheumatol 2017;35:462-470.
  17. Ougnou M, et al. Clinical Chemistry and Laboratory Medicine 2017;49:S215.
  18. Pereira LM, et al. (2010). “Evaluation of a novel automated CTD Screen for Connective Tissue Diseases.” EliA Journal (Special Edition 1): 6-7.
  19. Robier C, et al. Clinical Chemistry and Laboratory Medicine 2016;54(8):1365-1370.
  20. Sánchez-Castañón M, et al. (2010). “Evaluation of CTD Screen on the ImmunoCAP 100 System: Confirmed Diagnosis Samples and Consecutive Unknown Routine Samples.” EliA Journal (Special Edition 1): 8-9.
  21. van der Pol P, et al. Clin Chim Acta 2018;476:154-159.
  22. Viander M, et al. (2011). “Clinical evaluation of EliA CTD Screen in CTD patients and control samples in comparison to ANA immunofluorescence (IIF) on HEp-2 cells.” 10th Dresden Symposium on Autoantibodies, Dresden, September 2011.
  23. Watanabe N, et al. The Japanese journal of clinical pathology 2014; 62(4): 315-323.
  24. Willems P, et al. Clin Chem Lab Med 2018; 24: 909-918.